Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation: London, UK Saturday, August 9, 2025, 10:00 Hrs [IST] GSK plc announces that, in connection with th ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

Flutter Entertainment (FLTR) upped full-year guidance after a solid second quarter, with group revenue up 16 per cent to $4.2bn (£3.1bn) and adjusted Ebitda climbing 25 per cent to $919mn. Average ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...